Your browser doesn't support javascript.
Clinical sensitivity and interpretation of PCR and serological COVID-19 diagnostics for patients presenting to the hospital.
Miller, Tyler E; Garcia Beltran, Wilfredo F; Bard, Adam Z; Gogakos, Tasos; Anahtar, Melis N; Astudillo, Michael Gerino; Yang, Diane; Thierauf, Julia; Fisch, Adam S; Mahowald, Grace K; Fitzpatrick, Megan J; Nardi, Valentina; Feldman, Jared; Hauser, Blake M; Caradonna, Timothy M; Marble, Hetal D; Ritterhouse, Lauren L; Turbett, Sara E; Batten, Julie; Georgantas, Nicholas Zeke; Alter, Galit; Schmidt, Aaron G; Harris, Jason B; Gelfand, Jeffrey A; Poznansky, Mark C; Bernstein, Bradley E; Louis, David N; Dighe, Anand; Charles, Richelle C; Ryan, Edward T; Branda, John A; Pierce, Virginia M; Murali, Mandakolathur R; Iafrate, A John; Rosenberg, Eric S; Lennerz, Jochen K.
  • Miller TE; Department of Pathology, Massachusetts General Hospital/Harvard Medical School, Boston, MA, USA.
  • Garcia Beltran WF; Department of Pathology, Massachusetts General Hospital/Harvard Medical School, Boston, MA, USA.
  • Bard AZ; Department of Pathology, Massachusetts General Hospital/Harvard Medical School, Boston, MA, USA.
  • Gogakos T; Department of Pathology, Massachusetts General Hospital/Harvard Medical School, Boston, MA, USA.
  • Anahtar MN; Department of Pathology, Massachusetts General Hospital/Harvard Medical School, Boston, MA, USA.
  • Astudillo MG; Department of Pathology, Massachusetts General Hospital/Harvard Medical School, Boston, MA, USA.
  • Yang D; Department of Pathology, Massachusetts General Hospital/Harvard Medical School, Boston, MA, USA.
  • Thierauf J; Department of Pathology, Massachusetts General Hospital/Harvard Medical School, Boston, MA, USA.
  • Fisch AS; Department of Pathology, Massachusetts General Hospital/Harvard Medical School, Boston, MA, USA.
  • Mahowald GK; Department of Pathology, Massachusetts General Hospital/Harvard Medical School, Boston, MA, USA.
  • Fitzpatrick MJ; Department of Pathology, Massachusetts General Hospital/Harvard Medical School, Boston, MA, USA.
  • Nardi V; Department of Pathology, Massachusetts General Hospital/Harvard Medical School, Boston, MA, USA.
  • Feldman J; Ragon Institute of MGH, MIT, and Harvard, Cambridge, MA, USA.
  • Hauser BM; Ragon Institute of MGH, MIT, and Harvard, Cambridge, MA, USA.
  • Caradonna TM; Ragon Institute of MGH, MIT, and Harvard, Cambridge, MA, USA.
  • Marble HD; Department of Pathology, Massachusetts General Hospital/Harvard Medical School, Boston, MA, USA.
  • Ritterhouse LL; Department of Pathology, Massachusetts General Hospital/Harvard Medical School, Boston, MA, USA.
  • Turbett SE; Department of Pathology, Massachusetts General Hospital/Harvard Medical School, Boston, MA, USA.
  • Batten J; Division of Infectious Diseases, Department of Medicine, Massachusetts General Hospital/Harvard Medical School, Boston, MA, USA.
  • Georgantas NZ; Department of Pathology, Massachusetts General Hospital/Harvard Medical School, Boston, MA, USA.
  • Alter G; Department of Pathology, Massachusetts General Hospital/Harvard Medical School, Boston, MA, USA.
  • Schmidt AG; Ragon Institute of MGH, MIT, and Harvard, Cambridge, MA, USA.
  • Harris JB; Ragon Institute of MGH, MIT, and Harvard, Cambridge, MA, USA.
  • Gelfand JA; Division of Infectious Diseases, Department of Pediatrics, Massachusetts General Hospital/Harvard Medical School, Boston, MA, USA.
  • Poznansky MC; Division of Infectious Diseases, Department of Medicine, Massachusetts General Hospital/Harvard Medical School, Boston, MA, USA.
  • Bernstein BE; Division of Infectious Diseases, Department of Medicine, Massachusetts General Hospital/Harvard Medical School, Boston, MA, USA.
  • Louis DN; Department of Pathology, Massachusetts General Hospital/Harvard Medical School, Boston, MA, USA.
  • Dighe A; Department of Pathology, Massachusetts General Hospital/Harvard Medical School, Boston, MA, USA.
  • Charles RC; Department of Pathology, Massachusetts General Hospital/Harvard Medical School, Boston, MA, USA.
  • Ryan ET; Division of Infectious Diseases, Department of Medicine, Massachusetts General Hospital/Harvard Medical School, Boston, MA, USA.
  • Branda JA; Division of Infectious Diseases, Department of Medicine, Massachusetts General Hospital/Harvard Medical School, Boston, MA, USA.
  • Pierce VM; Department of Pathology, Massachusetts General Hospital/Harvard Medical School, Boston, MA, USA.
  • Murali MR; Department of Pathology, Massachusetts General Hospital/Harvard Medical School, Boston, MA, USA.
  • Iafrate AJ; Division of Infectious Diseases, Department of Pediatrics, Massachusetts General Hospital/Harvard Medical School, Boston, MA, USA.
  • Rosenberg ES; Department of Pathology, Massachusetts General Hospital/Harvard Medical School, Boston, MA, USA.
  • Lennerz JK; Division of Allergy and Immunology, Department of Medicine, Massachusetts General Hospital/Harvard Medical School, Boston, MA, USA.
FASEB J ; 34(10): 13877-13884, 2020 10.
Article in English | MEDLINE | ID: covidwho-733355
Preprint
This scientific journal article is probably based on a previously available preprint. It has been identified through a machine matching algorithm, human confirmation is still pending.
See preprint
ABSTRACT
The diagnosis of COVID-19 requires integration of clinical and laboratory data. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) diagnostic assays play a central role in diagnosis and have fixed technical performance metrics. Interpretation becomes challenging because the clinical sensitivity changes as the virus clears and the immune response emerges. Our goal was to examine the clinical sensitivity of two most common SARS-CoV-2 diagnostic test modalities, polymerase chain reaction (PCR) and serology, over the disease course to provide insight into their clinical interpretation in patients presenting to the hospital. We conducted a single-center, retrospective study. To derive clinical sensitivity of PCR, we identified 209 PCR-positive SARS-CoV-2 patients with multiple PCR test results (624 total PCR tests) and calculated daily sensitivity from date of symptom onset or first positive test. Clinical sensitivity of PCR decreased with days post symptom onset with >90% clinical sensitivity during the first 5 days after symptom onset, 70%-71% from Days 9 to 11, and 30% at Day 21. To calculate daily clinical sensitivity by serology, we utilized 157 PCR-positive patients with a total of 197 specimens tested by enzyme-linked immunosorbent assay for IgM, IgG, and IgA anti-SARS-CoV-2 antibodies. In contrast to PCR, serological sensitivity increased with days post symptom onset with >50% of patients seropositive by at least one antibody isotype after Day 7, >80% after Day 12, and 100% by Day 21. Taken together, PCR and serology are complimentary modalities that require time-dependent interpretation. Superimposition of sensitivities over time indicate that serology can function as a reliable diagnostic aid indicating recent or prior infection.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: COVID-19 Nucleic Acid Testing / COVID-19 Serological Testing / SARS-CoV-2 / COVID-19 Type of study: Diagnostic study / Observational study / Prognostic study Limits: Female / Humans / Male / Middle aged Language: English Journal: FASEB J Journal subject: Biology / Physiology Year: 2020 Document Type: Article Affiliation country: Fj.202001700RR

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: COVID-19 Nucleic Acid Testing / COVID-19 Serological Testing / SARS-CoV-2 / COVID-19 Type of study: Diagnostic study / Observational study / Prognostic study Limits: Female / Humans / Male / Middle aged Language: English Journal: FASEB J Journal subject: Biology / Physiology Year: 2020 Document Type: Article Affiliation country: Fj.202001700RR